1. FOLLOW-UP ON ACTION ITEMS

   a. Laurenz pointed working group members to the previous meeting notes and action items (see attachment 2)

2. UPDATE ON MEMBERSHIP AND ENGAGEMENT

   a. Safa provided an update that we now have 276 listserv members (see attachment 3)
   b. Janine described key findings from the membership survey (see attachment 4):
      1. One quarter of members responded
      2. Half are based in academic institutions
      3. One third are based in Canada (with at least four respondents from Brazil, Malaysia, Uganda and U.S.)
      4. Top 3 professional roles (using wording from our working groups) are recommending, packaging and scoping
      5. Top areas of interest are public-health measures and health-system arrangements (as two of the four parts of the COVID-END taxonomy) and evidence synthesis (as a methodology)
      6. Mix of those with very experienced and those with limited experience with evidence-informed decision-making (and the latter may be best served with basic information about how to use existing resources like the inventory and how to work through issues that are coming forward, such as wearing masks with people you know in crowded or poorly ventilated spaces, which will be the focus of five upcoming EVIPNet webinars)

3. SEQUENCE OF CONFIRMED TOPICS

   a. Maureen noted the plan to address the dissemination of reviews this week (facilitator: Ben Heaven Taylor)
   b. John noted that he had been planning to propose a topic related to the tensions between duplication and replication but, having heard Janine’s presentation, concluded that this would not be a good match to the likely needs of those with limited experience
   c. Janine and others noted that the responses to the upcoming webinar on COVID-END resources will be a good way to elicit ideas for where the COVID-END Community can best add value
   d. Several working group members suggested that it might be helpful to have a series of topics related to the resources to support decision-making in general and then for each of them in detail (when and how to use each of them)
   e. Maureen noted that it would be helpful to be able to signal to researchers what type of research would help to move a GRADE evidence profile from low to higher certainty
evidence (and John noted that GRADE will also need to grapple with how they incorporate outbreak studies)

4. SEQUENCE OF FUTURE TOPICS

a. Maureen reminded working group members of the running list of potential new topics/ideas for future weeks:
   i. Difference between expert opinion-based guidance and guidance developed using a robust process (potential facilitators: Ivan Florez and Per Olav Vandvik for mid-October)
   ii. Rapid response / review focused discussion (facilitator: Maureen Dobbins, date: TBD)
   iii. Discussion on LMICs paper led by Scoping WG
   iv. Long COVID (facilitator: Sandy Oliver, date: TBD)
   v. Series of topics related to the resources to support decision-making in general and then for each of them in detail (when and how to use each of them) (facilitator: Secretariat, date TBD)
   vi. Signaling to researchers what type of research would help to move a GRADE evidence profile from low to higher certainty evidence

5. WEBINARS FOR THE COVID-END COMMUNITY

a. Lauren reminded working group members of the upcoming list of webinar topics
   i. 14 October: Living hub of hubs (potential facilitators: Cristian Mansilla and Promise Nduku; co-branded with GESI)
   ii. November: Horizon scanning (facilitator: Heather Bullock, date and time TBD)
   iii. December: Tour of the COVID-END website and its resources (facilitator: John Lavis; brief presentations by leads for different resources profiled on the website)
   iv. January: Ensuring patients have access to research evidence that is as up-to-date as it is for other stakeholders (facilitator: Sandy Oliver, date and time TBD)
   v. Ideas for future topics:
      • Priority setting
      • LMIC paper
      • Global scene setting – e.g., Steven Hoffman on the UN COVID Recovery Research agenda, Lancet commission
      • Planning the next evidence phase for the pandemic (articulating the need for curated, high quality living stock of reviews addressing key questions)
      • A guide to COVID research resources for synthesis (we are beginning to map out the content coverage, strengths and weaknesses of the different evidence portals, etc.)
      • Working group specific presentation

6. ANY OTHER BUSINESS

a. John noted that there will be no scheduled COVID-END meetings (partners, co-chairs and working groups) for the following weeks:
i. Week of October 12

ii. Week of November 16